916141-36-1

Orexin receptors 1 (OX1R) and OX2R mediate the action of the neuropeptides orexin A and orexin B. TCS 1102 is a dual antagonist of both OX1R and OX2R (K_is = 0.2 and 3 nM, respectively). It is a poor substrate for P-glycoprotein and, as a result, demonstrates good brain penetration when administered intraperitoneally. Dual orexin receptor antagonists, including TCS 1102, promote sleep and prevent drug-induced plasticity and drug relapse. Systemic injection of TCS 1102 (10 mg/kg i.p.) in rats decreases fear and anxiety in response to acute episodes of stress.

TCS 1102 is a dual antagonist of both OX1R and OX2R. It is a poor substrate for P-glycoprotein and, as a result, demonstrates good brain penetration when administered intraperitoneally. Dual orexin receptor antagonists, including TCS 1102, promote sleep and prevent drug-induced plasticity and drug relapse.

OX₁ Receptor: 3 nM (Ki); OX₂ Receptor: 0.2 nM (Ki)

Store at RT

[1] JEFFREY M. BERGMAN . Proline bis-amides as potent dual orexin receptor antagonists[J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18 4: Pages 1425-1430. DOI: 10.1016/j.bmcl.2008.01.001
[2] CHRISTOPHER J. WINROW . Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure[J]. Neuropharmacology, 2010, 58 1: Pages 185-194. DOI: 10.1016/j.neuropharm.2009.07.008
[3] XIAOYU CHEN. Orexins (hypocretins) contribute to fear and avoidance in rats exposed to a single episode of footshocks.[J]. Brain Structure & Function, 2014, 219 6: 2103-2118. DOI: 10.1007/s00429-013-0626-3